LABT
Lakewood-Amedex Biotherapeutics Inc.
Key Financials
Operating Income
$-886750
N/A
EPS (Diluted)
$-0.20
N/A
Net Income
$-923291
N/A
Total Liabilities
$3.0M
N/A
Total Assets
$196343.00
N/A
Cash & Equivalents
$11709.00
N/A
Shareholders' Equity
$-2841648.00
N/A
Operating Cash Flow
$-349691.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/17/2026 | View on SEC |
| 424B3 | 5/26/2026 | View on SEC |
| 424B3 | 5/26/2026 | View on SEC |
| 10-Q | 5/22/2026 | View on SEC |
| 424B4 | 5/14/2026 | View on SEC |
| EFFECT | 5/13/2026 | View on SEC |
| CORRESP | 5/12/2026 | View on SEC |
| UPLOAD | 5/8/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 3 | 5/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LABT |
| Company Name | Lakewood-Amedex Biotherapeutics Inc. |
| CIK | 2079272 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 9412252515 |